The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of panitumumab, 5-fluorouracil, mitomycin-c and radiotherapy treatment in patients with non-metastatic squamous cell carcinoma of the anal canal: safety and efficacy results (VITAL study)—GEMCAD 09-02.
 
Jaime Feliu
No Relationships to Disclose
 
Rocio Garcia-Carbonero
Honoraria - AstraZeneca (I); Boehringer Ingelheim (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CELGENE (I); IPSEN; Lilly (I); MERCK; Merck (I); MSD; MSD (I); Novartis; Novartis (I); PFIZER; Pfizer (I); ROCHE; Roche (I); SERVIER
Consulting or Advisory Role - AstraZeneca (I); Boehringer Ingelheim (I); Bristol-Myers Squibb (I); IPSEN; Lilly (I); Merck Sharp & Dohme (I); MSD; Novartis (I); Pfizer (I); Roche (I)
Research Funding - PFIZER
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim (I); Ipsen; Lilly (I); Merck; Novartis; Pfizer; Pfizer (I); Roche; Roche (I); Sanofi
 
Jaume Capdevila
No Relationships to Disclose
 
Inmaculada Guasch
No Relationships to Disclose
 
Vicente Alonso
No Relationships to Disclose
 
Carlos López-López
Honoraria - Amgen; Roche
Consulting or Advisory Role - Amgen; Roche
Speakers' Bureau - Amgen; Roche
Research Funding - Amgen; Roche
 
Pilar Garcia Alfonso
No Relationships to Disclose
 
Carmen Castañon Lopez
No Relationships to Disclose
 
Isabel Sevilla
Consulting or Advisory Role - Amgen; Ipsen; Novartis
Speakers' Bureau - Ipsen; Novartis
 
Joan Maurel
No Relationships to Disclose